Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
The Loulou Foundation has enabled significant progress in the understanding and treatment of CDKL5 Deficiency Disorder by supporting preclinical and clinical studies, including the CANDID observational study. It has fostered industry-academic collaborations that have led to investigational therapies reaching clinical trials, such as ganaxolone by Marinus Pharmaceuticals receiving FDA Rare Pediatric Disease Designation for CDD. The foundation’s efforts have contributed to the recognition of CDD as a reversible condition at the biological level, increasing hope for restorative treatments.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Loulou Foundation.